Literature DB >> 2182265

Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.

Y W Lam1, A M Shepherd.   

Abstract

Antihypertensive treatment has proven benefits, and the number of patients being treated with these drugs is significant. Hypertensive patients may have other medical illnesses for which they receive medications, and interactions between antihypertensive agents and other drugs is likely. Some of these interactions may lead to undesirable effects or even loss of blood pressure control. However, drug interactions can also be beneficial when 2 antihypertensive drugs with different pharmacological actions are prescribed in combination and with a clear therapeutic objective in mind. Clinicians should be aware of the mechanisms and the consequences of the different types of interaction in hypertensive patients, so that a desired pharmacological response can be achieved with the fewest side effects in the patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2182265     DOI: 10.2165/00003088-199018040-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  156 in total

1.  Inhibition of propranolol metabolism by chlorpromazine.

Authors:  R E Vestal; D M Kornhauser; J W Hollifield; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

2.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

Review 3.  Effects of pseudoephedrine in man.

Authors:  D T Hughes; D W Empey; M Land
Journal:  J Clin Hosp Pharm       Date:  1983-12

4.  The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.

Authors:  M S Lennard; P R Jackson; S Freestone; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

5.  Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.

Authors:  J Watkins; E C Abbott; C N Hensby; J Webster; C T Dollery
Journal:  Br Med J       Date:  1980-09-13

6.  Veterans Administration cooperative study on nadolol as monotherapy and in combination with a diuretic.

Authors:  E D Freis
Journal:  Am Heart J       Date:  1984-10       Impact factor: 4.749

7.  Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.

Authors:  D Gangji; M Juvent; G Niset; M Wathieu; M Degreve; R Bellens; J Poortmans; S Degre; T J Fitzsimons; A Herchuelz
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

8.  Flurbiprofen interaction with single doses of atenolol and propranolol.

Authors:  J Webster; J C Petrie; I McLean; G M Hawksworth
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

Review 9.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

10.  Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine.

Authors:  M Peet; D N Middlemiss; R A Yates
Journal:  Br J Psychiatry       Date:  1981-08       Impact factor: 9.319

View more
  2 in total

Review 1.  The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.

Authors:  C Knott
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 2.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.